DCLK1 and neoplasm: Our study revealed that DCLK1-promoted stemness significantly decreased the sensitivity of TNBC cells to chemotherapy drugs including cisplatin and doxorubicin, and DCLK1 knockout increased the sensitivity, which suggested the combination of DCLK1 inhibitor with chemotherapeutics might be a promising therapeutic strategy for TNBC patients with drug resistance and tumor recurrence.